SCHEMBL3696551

SCHEMBL3696551

Cc1cn([C@]2([SiH](c3ccccc3)c3ccccc3)O[C@H](CO)[C@@H](O)[C@]2(OCCO)C(C)(C)C)c(=O)[nH]c1=O

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RNASE1 P07998 1/20 0.36
TYMP P19971 1/20 0.35
TK2 O00142 5/20 0.33
TK1 P04183 5/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6421057 0.92 RNASE1 (0.34) RNASE1TYMPTK2TK1HPGD
SCHEMBL5668670 0.84 RNASE1 (0.37) RNASE1TYMPTK2TK1HPGD
SCHEMBL4952762 0.83 TK2 (0.39) RNASE1TYMPTK2TK1HPGD
SCHEMBL4949400 0.77 TK2 (0.36) RNASE1TYMPTK2TK1
SCHEMBL4470358 0.76 TK2 (0.34) RNASE1TYMPTK2TK1HPGD
SCHEMBL7639912 0.76 TK1 (0.34) RNASE1TK2TK1HPGD
SCHEMBL9396549 0.75 RNASE1 (0.39) RNASE1TK2TK1
SCHEMBL6223881 0.75 TK2 (0.33) RNASE1TYMPTK2TK1
SCHEMBL7195757 0.74 TK1 (0.33) TK2TK1
SCHEMBL261290 0.73 TK1 (0.33) RNASE1TK2TK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7723508-B2 a single-stranded antisense oligonucleotide, targeted to nucleic acid encoding lipid-free protein constituents of plasma lipoproteins, used for diagnosis and therapy of cardiovascular disorders, including myocardial infarction and atherosclerosis ISIS PHARMACEUTICALS, INC. (US) 2010-05-25 US disclosed
US-20060281698-A1 a single-stranded antisense oligonucleotide, targeted to nucleic acid encoding lipid-free protein constituents of plasma lipoproteins, used for diagnosis and therapy of cardiovascular disorders, including myocardial infarction and atherosclerosis IONIS PHARMACEUTICALS, INC. 2006-12-14 US disclosed
EP-1442046-A4 MAMMALIAN C-TYPE LECTINS IMMUNEX CORP (US) 2005-08-31 EP disclosed
EP-1442046-A2 MAMMALIAN C-TYPE LECTINS Immunex CorporatioN (US) 2004-08-04 EP disclosed
WO-2003031578-A2 MAMMALIAN C-TYPE LECTINS IMMUNEX CORPORATION (US) 2003-04-17 WO disclosed